Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Abderrezek, ELALOUANI"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    Item
    In silico study of the anti-xanthine oxidase activity of certain metabolites derived from marine sponges
    (Faculté des Sciences de la Nature et de la Vie et Sciences de la Terre. Université de Ghardaïa, 2025) Abderrezek, ELALOUANI
    This study investigates the therapeutic potential of five marine-derived metabolites as inhibitors of human xanthine oxidase (HXO), a critical enzymatic target in the treatment of gout an inflammatory disorder caused by the deposition of monosodium urate crystals in joints and surrounding tissues. Two alkaloids, Petrosin (Mol1) and Xestospongin D (Mol2), were selected from the marine sponge Oceanapia sp. A phenolic acid, Gentisic acid (Mol3), was obtained from Hemimycale columella. Additionally, two sesquiterpenoids, Sydonol (Mol4) and Aspergiterpenoid A (Mol5), were derived from a fungal strain (Aspergillus sp.) isolated from the sponge Xestospongia testudinaria. Molecular docking analysis using AutoDock Vina revealed that Mol1 and Mol2 exhibit the strongest binding affinities toward HXO, with binding energies of -11.5 kcal/mol and -8.8 kcal/mol, respectively significantly surpassing the reference drug allopurinol (-5.9 kcal/mol). Mol3, Mol4, and Mol5 also demonstrated enhanced binding stability compared to allopurinol. Complementary ADMT (absorption, distribution, metabolism, and toxicity) predictions indicated favorable pharmacokinetic properties and safety profiles, including low carcinogenic potential and minimal risk for cardiotoxicity. Collectively, these in silico findings underscore the promise of marine-derived metabolites, particularly Mol1 and Mol2, as novel HXO inhibitors that may lead to safer and more effective gout treatments. Further in vitro and in vivo validation is warranted to confirm these results.

DSpace software copyright © 2002-2026 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify